Safety and Durability of Sirolimus for Treatment of LAM
The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.
Checked against the public recordLast updated Dec 24, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Cincinnati
- Interventions being studied
- Drug: Sirolimus; Drug: Everolimus
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Female or male, age 18 or over * Diagnosis of LAM based on ATS/JRS criteria * Signed and dated informed consent * On chronic therapy, newly treated or may be considered for therapy with mTOR inhibitors or previously intolerant of or having failed mTOR inhibitor therapy Exclusion Criteria: * Inability to attend at least one RLD Clinic visit per year * Inability to give informed consent * Inability or unwillingness to perform pulmonary function testing
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Stanford University Medical CenterStanford, California
- National Jewish HealthDenver, Colorado
- Mayo Clinic JacksonvilleJacksonville, Florida
- Emory University School of MedicineAtlanta, Georgia
- Loyola University Medical Center, ChicagoMaywood, Illinois
- Brigham and Women's HospitalBoston, Massachusetts
- University of MichiganAnn Arbor, Michigan
- Mayo Clinic RochesterRochester, Minnesota
- Washington University School of MedicineSt Louis, Missouri
- University of Rochester Medical CenterRochester, New York
- University of CincinnatiCincinnati, Ohio
- Cleveland ClinicCleveland, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 24, 2024. Always confirm current availability with the study team.